Literature DB >> 24463418

Evidence-based management of primary angle closure glaucoma.

Matthew E Emanuel1, Richard K Parrish, Steven J Gedde.   

Abstract

PURPOSE OF REVIEW: To review the classification of primary angle closure (PAC) and discuss the evidence-based management of each type. RECENT
FINDINGS: There is limited evidence to support the prophylactic treatment of primary angle closure suspects. Cataract and clear lens extraction may be more effective than traditional therapy in controlling intraocular pressure (IOP) in patients with PAC, primary angle closure glaucoma, and acute angle closure crisis.
SUMMARY: Treatment of angle closure depends on the signs of chronic angle damage and glaucomatous optic neuropathy. In the absence of such evidence, serial gonioscopy may be the preferred therapy. If signs or symptoms are present, medical therapy and laser peripheral iridotomy are beneficial. However, recent data suggest that cataract extraction may be more effective at controlling the IOP than laser or incisional glaucoma procedures.

Entities:  

Mesh:

Year:  2014        PMID: 24463418     DOI: 10.1097/ICU.0000000000000028

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  15 in total

1.  Comparison of phacotrabeculectomy and sequential surgery in the treatment of chronic angle-closure glaucoma coexisted with cataract.

Authors:  Hai-Jun Li; Jie Xuan; Xiao-Min Zhu; Lin Xie
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

2.  Evaluation of the efficacy of laser peripheral iridoplasty in reversing the darkroom provocative test result in Chinese patients with primary angle closure status post laser iridotomy.

Authors:  Ping Huang; Ling-Ling Wu
Journal:  Int J Ophthalmol       Date:  2015-06-18       Impact factor: 1.779

3.  Iridotomy to slow progression of angle-closure glaucoma.

Authors:  Jimmy T Le; Benjamin Rouse; Gus Gazzard
Journal:  Cochrane Database Syst Rev       Date:  2016-06-29

4.  Corneal hysteresis and anterior segment optical coherence tomography anatomical parameters in primary angle closure suspects.

Authors:  Syed Amal Hussnain; Kyle D Kovacs; Joshua L Warren; Christopher C Teng
Journal:  Clin Exp Ophthalmol       Date:  2018-01-11       Impact factor: 4.207

5.  Comparison of ultrasound biomicroscopy and spectral-domain anterior segment optical coherence tomography in evaluation of anterior segment after laser peripheral iridotomy.

Authors:  Xiao-Yun Ma; Dan Zhu; Jun Zou; Wen-Jie Zhang; Yi-Lin Cao
Journal:  Int J Ophthalmol       Date:  2016-03-18       Impact factor: 1.779

6.  Non-contact tests for identifying people at risk of primary angle closure glaucoma.

Authors:  Anish Jindal; Irene Ctori; Gianni Virgili; Ersilia Lucenteforte; John G Lawrenson
Journal:  Cochrane Database Syst Rev       Date:  2020-05-28

7.  Improving Access to Eye Care among Persons at High-Risk of Glaucoma in Philadelphia--Design and Methodology: The Philadelphia Glaucoma Detection and Treatment Project.

Authors:  Lisa Hark; Michael Waisbourd; Jonathan S Myers; Jeffrey Henderer; John E Crews; Jinan B Saaddine; Jeanne Molineaux; Deiana Johnson; Harjeet Sembhi; Shayla Stratford; Ayman Suleiman; Laura Pizzi; George L Spaeth; L Jay Katz
Journal:  Ophthalmic Epidemiol       Date:  2016-03-07       Impact factor: 1.648

Review 8.  Iridotomy to slow progression of visual field loss in angle-closure glaucoma.

Authors:  Jimmy T Le; Benjamin Rouse; Gus Gazzard
Journal:  Cochrane Database Syst Rev       Date:  2018-06-13

9.  Primary angle-closure glaucoma: A retrospective interventional case series in South India.

Authors:  H H Suresh; H R Samhitha; H Kishore; Krishna Prasad; Sneha Solse; P Divya
Journal:  Oman J Ophthalmol       Date:  2016 Jan-Apr

10.  In vivo Confocal Microscopy of Posner-Schlossman Syndrome: Comparison with herpes simplex keratitis, HLA-B27 anterior uveitis and acute attack of primary angle closure.

Authors:  Ying Hong; Miao Wang; Lingling Wu
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.